COVID-19 drug discovery using intensive approaches

Ayumu Asai, Masamitsu Konno, Miyuki Ozaki, Chihiro Otsuka, Andrea Vecchione, Takahiro Arai, Toru Kitagawa, Ken Ofusa, Masami Yabumoto, Takaaki Hirotsu, Masateru Taniguchi, Hidetoshi Eguchi, Yuichiro Doki, Hideshi Ishii

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)


Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.

Original languageEnglish
Article number2839
JournalInternational journal of molecular sciences
Issue number8
Publication statusPublished - 2 Apr 2020


  • COVID-19
  • Coronavirus
  • Drug discovery
  • Drug repositioning
  • Infection


Dive into the research topics of 'COVID-19 drug discovery using intensive approaches'. Together they form a unique fingerprint.

Cite this